We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+11.15%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$8.8B
AUM Growth
-$819M
(-8.5%)
Cap. Flow
-$1.49B
Cap. Flow
% of AUM
-16.94%
Top 10 Holdings %
Top 10 Hldgs %
37.49%
Holding
1,086
New
112
Increased
123
Reduced
630
Closed
126
Avg Time Held Equity + Options
3.2
quarters
Top 10 Avg Time Held Equity + Options
0.5
quarters
Top 20 Avg Time Held Equity + Options
0.7
quarters
Avg Time Held Equity only
3.2
quarters
Top 10 Avg Time Held Equity only
0.5
quarters
Top 20 Avg Time Held Equity only
0.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVLR
Avalara, Inc.
AVLR
|
+$364M |
| 2 |
ZEN
ZENDESK INC
ZEN
|
+$355M |
| 3 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$273M |
| 4 |
STOR
STORE Capital Corporation
STOR
|
+$213M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$138M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACC
American Campus Communities, Inc.
ACC
|
+$463M |
| 2 |
CTXS
Citrix Systems Inc
CTXS
|
+$411M |
| 3 |
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
|
+$317M |
| 4 |
CDK
CDK Global, Inc.
CDK
|
+$290M |
| 5 |
MNDT
Mandiant, Inc. Common Stock
MNDT
|
+$276M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.43% |
| 2 | Financials | 19.77% |
| 3 | Healthcare | 15.9% |
| 4 | Miscellaneous | 8.89% |
| 5 | Real Estate | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
626
Aclaris Therapeutics
ACRS
$511M
| $1.78M | 0.02% |
113,426
| – | – |
2022 Q1
2 quarters
|
|
627
DELISTED
Crinetics Pharmaceuticals
CRNX
| $1.78M | 0.02% |
90,460
+3,000
| +3% | +$61.2K |
2022 Q1
2 quarters
|
|
628
Rhythm Pharmaceuticals
RYTM
$5.96B
| $1.77M | 0.02% |
+72,375
| New | +$1.35M |
2022 Q3
0 quarters
|
|
629
DELISTED
Concord Acquisition Corp II
CNDA
| $1.77M | 0.02% |
182,069
-18,227
| -9% | -$177K |
2021 Q4
3 quarters
|
|
630
EQT Corp
EQT
$34B
| $1.76M | 0.02% |
43,181
+19,220
| +80% | +$834K |
2021 Q3
4 quarters
|
|
631
Glaukos
GKOS
$9.76B
| $1.74M | 0.02% |
32,692
-7,800
| -19% | -$403K |
2022 Q1
2 quarters
|
|
632
PUT
Carnival Corporation Ltd
CCL
$35.9B
| $1.72M | 0.02% |
1,006,000
+257,500
| +34% | +$2.49M |
2021 Q3
4 quarters
|
|
633
Phathom Pharmaceuticals
PHAT
$566M
| $1.71M | 0.02% |
154,093
+27,000
| +21% | +$257K |
2022 Q1
2 quarters
|
|
634
Eastman Chemical
EMN
$7.2B
| $1.7M | 0.02% |
+23,941
| New | +$2.15M |
2022 Q3
0 quarters
|
|
635
Penumbra
PEN
$12.6B
| $1.69M | 0.02% |
8,907
+2,900
| +48% | +$465K |
2022 Q1
2 quarters
|
|
636
Marriott Vacations Worldwide
VAC
$3.73B
| $1.69M | 0.02% |
13,853
-36,548
| -73% | -$4.96M |
2022 Q1
2 quarters
|
|
637
Omega Healthcare
OHI
$13.7B
| $1.69M | 0.02% |
57,145
-7,834
| -12% | -$246K |
2022 Q2
1 quarter
|
|
638
OrthoPediatrics
KIDS
$573M
| $1.68M | 0.02% |
36,448
-8,500
| -19% | -$417K |
2022 Q1
2 quarters
|
|
639
DELISTED
RAPT Therapeutics
RAPT
| $1.68M | 0.02% |
8,727
-1,117
| -11% | -$211K |
2022 Q2
1 quarter
|
|
640
Viridian Therapeutics
VRDN
$2.06B
| $1.68M | 0.02% |
81,870
+47,481
| +138% | +$854K |
2022 Q1
2 quarters
|
|
|
EIGR
641
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.67M | 0.02% |
7,401
-2,742
| -27% | -$674K |
2022 Q1
2 quarters
|
|
|
HHLA
642
DELISTED
HH&L Acquisition Co.
HHLA
| $1.67M | 0.02% |
167,609
-16,779
| -9% | -$166K |
2021 Q3
4 quarters
|
|
|
HORI
643
DELISTED
Emerging Markets Horizon Corp. Class A Ordinary Shares
HORI
| $1.64M | 0.02% |
163,767
-16,395
| -9% | -$163K |
2022 Q1
2 quarters
|
|
644
Immunocore
IMCR
$1.43B
| $1.63M | 0.02% |
34,697
-22,800
| -40% | -$1.09M |
2022 Q1
2 quarters
|
|
|
BRIV
645
DELISTED
B. Riley Principal 250 Merger Corp. Class A common stock
BRIV
| $1.62M | 0.02% |
165,166
-16,535
| -9% | -$162K |
2021 Q3
4 quarters
|
|
646
MasTec
MTZ
$16.6B
| $1.6M | 0.02% |
25,228
-57,800
| -70% | -$4.47M |
2020 Q4
7 quarters
|
|
647
DELISTED
Skydeck Acquisition Corp. Class A Ordinary Shares
SKYA
| $1.6M | 0.02% |
161,980
-16,216
| -9% | -$159K |
2021 Q3
4 quarters
|
|
648
Agenus
AGEN
$314M
| $1.59M | 0.02% |
39,639
+4,081
| +11% | +$208K |
2022 Q1
2 quarters
|
|
649
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $1.59M | 0.02% |
326,451
-6,800
| -2% | -$42.7K |
2022 Q1
2 quarters
|
|
650
Biogen
BIIB
$33.8B
| $1.59M | 0.02% |
+5,950
| New | +$1.26M |
2022 Q3
0 quarters
|
|
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q3 2022 Portfolio in Review
As of Q3 2022, UBS O'Connor held 1,086 positions worth $8.8B, down 8.5% from $9.62B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
UBS O'Connor withdrew a net $1.49B in Q3 2022, closing 126 positions and reducing 630 holdings. Its most notable exit was American Campus Communities, Inc., an estimated $463M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 28% a quarter earlier, followed by Financials and Healthcare.
Against the trend, UBS O'Connor opened a new position in Avalara, Inc. worth $373M.
- UBS O'Connor's largest Q3 2022 buy was Avalara, Inc.: 4,065,318 shares worth $373M.
- UBS O'Connor added most to ZENDESK INC in Q3 2022, an estimated $355M increase.
- UBS O'Connor's biggest Q3 2022 reduction was TSMC, cutting an estimated $77.7M.
- UBS O'Connor fully exited American Campus Communities, Inc. in Q3 2022, selling an estimated $463M.
- UBS O'Connor's ten largest holdings make up 37% of its $8.8B portfolio in Q3 2022.
- UBS O'Connor opened 112 new positions and closed 126 in Q3 2022.
- UBS O'Connor's portfolio value fell 8.5% quarter-over-quarter to $8.8B.
Based on UBS O'Connor's 13F filing for Q3 2022, filed 14 Nov 2022.